Home Blog of Signal Transduction Microbiology Reverse Transcriptase

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Reverse Transcriptase

Comparative analysis of pre-existing HIV drug resistance mutations in proviral DNA via Next-Generation Sequencing and routine HIV RNA genotyping

222 views | May 08 2023

The study found that deep sequencing of archived HIV DNA can detect transmitted drug resistance mutations that are not identified by routine bulk sequencing, including low-frequency mutations that could become dominant under drug selection pressure. [Read the Full Post]

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

90 views | May 07 2023

The study found that the lipid-lowering effect of DOR in people living with HIV was observed in those switching from other NNRTIs and INSTI-including regimens, but not in those switching from RPV, suggesting that the effect is drug class-related. [Read the Full Post]

Factors Associated With Adherence to First-line Antiviral Therapy Among Commercially Insured Patients With Chronic Hepatitis B

95 views | May 01 2023

The study found that longer-duration supplies of entecavir and TDF and use of mail order pharmacies may improve adherence among patients with CHB, while high out-of-pocket costs for TDF were associated with reduced medication adherence. [Read the Full Post]

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

77 views | May 01 2023

The study found that the 2-drug regimen of dolutegravir (DTG) + lamivudine (3TC) offers comparable and durable efficacy with fewer serious adverse events compared to two 3-drug single-tablet regimens in antiretroviral therapy-naive people with HIV-1 at Week 144 after treatment initiation. [Read the Full Post]

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver-child dyads' perspective

194 views | May 01 2023

The study found that caregivers in Uganda found the new 4-in-1 strawberry-flavoured granules formulation highly acceptable for children living with HIV compared to previous formulations, with factors such as appealing taste, ease of administration, and comprehensive healthcare provider support contributing to its acceptability. [Read the Full Post]

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study

136 views | Apr 27 2023

The study investigated the association between CYP2B6 polymorphisms and efavirenz drug resistance among women living with HIV who started on antiretroviral therapy during pregnancy and had high viremia in the postpartum period, and found no statistically significant difference in EFV resistance between EFV metabolizer genotypes, but a numerical trend was observed, calling for further confirmation in a large, well-designed, statistically powered study. [Read the Full Post]

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

85 views | Mar 05 2023

The study identified factors that limit or enhance immune recovery in PLWHIV after switching to DTG plus 3TC and may help clinicians predict treatment effects on immunological responses before the switch. [Read the Full Post]

Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis

87 views | Mar 05 2023

This study used a network meta-analysis to compare the effectiveness of different NAs in reducing reactivation of HBV, chemotherapy disruption, and improving survival in oncology patients with HBV, finding that lamivudine and entecavir were effective in prolonging survival, while tenofovir was best for reducing chemotherapy disruption. [Read the Full Post]

Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale

172 views | Mar 05 2023

The study investigated hOAT1 transport function, modulation of activity, and transport dysfunctions arising from mutations using molecular dynamics simulations and proposed a structural rationalization of the observations. [Read the Full Post]

Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial

93 views | Mar 05 2023

The Early Infant Treatment Study in Botswana found that initiating antiretroviral treatment in the first week of life led to positive clinical outcomes and low viral reservoir through 96 weeks, with pre-ART reservoir size at birth predicting the viral reservoir at 84/96 weeks. [Read the Full Post]